Title
Creating commercial opportunities for regenerative medicine by introducing closed, automated solutions with single-use principles
Conference Dates
September 23-26, 2018
Abstract
Cell and gene therapy, with growing proof of efficacy in varied indications, has reached an inflection point resulting in a steep increase in the investment of time and money by established companies and disruptive startups. With rapid growth comes the need to quickly and economically manufacture therapies that maintain a consistent, high-level of quality and, in turn, can support commercial manufacturing. This is especially true when looking at patient specific cell therapies that require rapid change over of equipment and benefit little from traditional sterile barriers (i.e. filters and heat inactivation) or economies of scale. Counter-flow centrifugation (CFC) presents an intriguing technology that, when implemented onto a closed and automated system, provides a platform for upstream processing of cell therapies by incorporating multiple unit processes and mitigating the risk imposed with frequent equipment changes.
Please click Additional Files below to see the full abstract.
Recommended Citation
Matthew Marsh, Alex Klarer, and David Smith, "Creating commercial opportunities for regenerative medicine by introducing closed, automated solutions with single-use principles" in "Single-Use Technologies III: Scientific and Technological Advancements", Weibing Ding, Amgen Martina Micheletti, University College London Robert Repetto, Pfizer Eds, ECI Symposium Series, (2018). https://dc.engconfintl.org/sut_iii/41